Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2), 5810(c)(3)(A)
Exact text from the filing
July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), for the previous 30 consecutive trading day period. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided with a 180-calendar day period to regain compliance with t
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
FibroBiologics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
December 30, 2025, the Company received a second notification indicating that the Staff planned to delist the Company’s securities due to the Company’s continued non-compliance with the Rule as of December 29, 2025, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by the Staff at least pending the outcome of the hearing and the expiration of any extension that may be granted to the Company by the Panel. The Company intend
View on SEC.gov